IP Library Granted Patent US 10,632,066
Granted Patent B1
US 10,632,066 · App. 16/265,222 · Granted Apr 28, 2020

Method of providing birth control

Inventors: George William Creasy, II (Glen Gardner, NJ); Ruth Beverly Merkatz (Rye, NY)
Assignee: The Population Council, Inc.
A61K9/0036A61F6/04A61F6/065A61K31/565A61K31/57
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,632,066
App. No.
16/265,222
Granted
Apr 28, 2020
Kind
B1
Abstract

The present disclosure describes a vaginal system comprising segesterone acetate and ethinyl estradiol configured for thirteen 28-day product-use cycles that is compatible with male condoms comprising natural rubber latex, polyisoprene, or polyurethane and a method of providing birth control using the vaginal system wherein a secondary contraception is employed when the vaginal system is removed or expelled from the vagina for specified amounts of time during any of the product-use cycles.

Claims (31)

1. A method of providing birth control, the method comprising:

(a) initially inserting into the vagina of a female of reproductive potential on either day 2, 3, 4, or 5 of the female's menstrual cycle, a vaginal system comprising:

a silicone elastomer ring body, a first channel within the ring body, a second channel within the ring body, a first core disposed within the first channel, a second core disposed within the second channel, 103 mg of segesterone acetate, and 17.4 mg ethinyl estradiol, wherein the 103 mg of segesterone acetate is distributed throughout the first core and the second core; and wherein one of the first or second cores contains the 17.4 mg of ethinyl estradiol;

wherein the system releases an average of approximately 0.15 mg/day of segesterone acetate and an average of approximately 0.013 mg/day of ethinyl estradiol in a 21-day first period as measured across thirteen 28-day product-use cycles; and

wherein the initial insertion on day 2, 3, 4, or 5 is the first day of the 21-day first period;

(b) removing the vaginal system from the female's vagina for more than two cumulative hours during the 21-day first period;

(c) reinserting the vaginal system into the vagina of the female of reproductive potential following the removal of the vaginal system from the female's vagina in step (b) and employing a secondary contraception product that does not comprise estrogen for seven days after reinserting the vaginal system;

(d) removing the vaginal system on the day following the end of the 21-day first period;

(e) storing the removed vaginal system for a second period of between five and seven days including the removal date of step (d), wherein the 21-day first period and second period together comprise a product-use cycle; and

(f) repeating steps (a), (d), and (e), and optionally repeating steps (b) and (c), for a total of up to thirteen product-use cycles including a first product-use cycle, wherein each initial insertion of step (a) is performed at approximately the same time of day as in a previous product-use cycle.

2. The method of claim 1 , further comprising storing the vaginal system at room temperature when the vaginal system is removed from the vagina.

3. The method of claim 1 , wherein removing the vaginal system from the female's vagina for more than two cumulative hours during the 21-day first period occurs in two or more instances on the same day, in two or more instances on consecutive or nonconsecutive days, or via a combination of occurrences on the same and different days.

4. The method of claim 1 , wherein removing the vaginal system in step (b) comprises intentionally removing the system or expelling the system.

5. The method of claim 1 , wherein the secondary contraception product that does not comprise estrogen is a male condom.

6. A method of providing birth control over the course of thirteen 28-day product-use-cycle, the method comprising:

(a) initially inserting into the vagina of a female of reproductive potential on either day 2, 3, 4, or 5 of the female's menstrual cycle, a vaginal system comprising:

a silicone elastomer ring body, a first channel within the ring body, a second channel within the ring body, a first core disposed within the first channel, a second core disposed within the second channel, 103 mg of segesterone acetate, and 17.4 mg ethinyl estradiol, wherein the 103 mg of segesterone acetate is distributed throughout the first core and the second core; and wherein one of the first or second cores contains the 17.4 mg of ethinyl estradiol;

wherein the system releases an average of approximately 0.15 mg/day of segesterone acetate and an average of approximately 0.013 mg/day of ethinyl estradiol in a 21-day first period as measured across thirteen 28-day product-use cycles; and

wherein the initial insertion on day 2, 3, 4, or 5 is the first day of the 21-day first period;

(b) removing the vaginal system from the female's vagina for more than two cumulative hours during the 21-day first period;

(c) storing the removed vaginal system for a second period of between five and seven days including the removal date of step (d), wherein the 21-day first period and second period together comprise a product-use cycle; and

(d) repeating steps (a), (b), and (c) for a total of up to thirteen product-use cycles including a first product-use cycle, wherein each initial insertion of step (a) is performed at approximately the same time of day as in a previous product-use cycle;

the method further comprising:

(e) removing the vaginal system from the female's vagina for more than two cumulative hours during at least one of the 21-day first periods in any of the thirteen product-use cycles;

(f) reinserting the vaginal system into the female's vagina following the removal of the vaginal system from the female's vagina in step (e); and

(g) employing a secondary contraception product that does not comprise estrogen for seven days after reinserting the vaginal system into the female's vagina.

7. The method of claim 6 , wherein removing the vaginal system from the female's vagina for more than two cumulative hours comprises intentionally, removing the vaginal system for more than two cumulative hours or unintentionally removing the vaginal system for more than two cumulative hours, or wherein removing the vaginal system for more than two cumulative hours comprises a combination of intentional and unintentional removals.

8. The method of claim 7 , wherein unintentionally removing the vaginal system comprises expelling the vaginal system.

9. The method of claim 6 , wherein the two cumulative hours out of the vagina are achieved via at least two instances wherein the vaginal system is removed from the vagina during the 21-day first period.

10. The method of claim 9 , wherein the at least two instances take place on the same days or different days.

11. The method of claim 10 , wherein the different days are consecutive different days or nonconsecutive different days.

Assignments (5)
TERMINATION AND RELEASE OF GRANT OF A SECURITY INTEREST - PATENTS Recorded Dec 30, 2022
From: SIXTH STREET SPECIALTY LENDING, INC. (F/K/A TPG SPECIALTY LENDING, INC.)
To: THERAPEUTICSMD, INC.
Reel/Frame 062254/0813 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 16, 2021
From: VARIANO, BRUCE
To: THE POPULATION COUNCIL, INC.
Reel/Frame 055609/0463 →
PARTIAL RELEASE OF SECURITY INTEREST IN CERTAIN PATENTS Recorded Aug 20, 2019
From: TPG SPECIALTY LENDING, INC.
To: THERAPEUTICSMD, INC.
Reel/Frame 050110/0955 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 8, 2019
From: CREASY, GEORGE WILLIAM, II; MERKATZ, RUTH BEVERLY
To: THE POPULATION COUNCIL, INC.
Reel/Frame 049113/0285 →
PATENT SECURITY AGREEMENT Recorded Apr 24, 2019
From: THERAPEUTICSMD, INC.
To: TPG SPECIALTY LENDING, INC.
Reel/Frame 048990/0820 →
Cited By (1)
US 12,702,641